Massachusetts
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Massachusetts: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Massachusetts adheres to the principle established in Myriad Genetics that naturally occurring genes cannot be patented, focusing on the public interest in accessing genetic information. The state emphasizes the balance between innovation in biotechnology and the need to keep fundamental genetic discoveries free for public usage.
In Massachusetts, the rule from Myriad will influence patentability assessments under the state’s intellectual property laws, particularly in cases involving genetic material or related biotechnological inventions.
The court found that patents must describe specific utility when claiming biological constructs, emphasizing that broad claims without clear distinctiveness could be rejected.
The court ruled that patents claiming broadly on naturally-derived substances are ineligible, reinforcing Myriad’s precedent regarding the non-patentability of natural products.
This case reinforced that the discovery of gene sequences, without significant alteration or application, does not grant patent rights under Massachusetts law.
Massachusetts's approach directly aligns with the federal standard set in Myriad Genetics, recognizing the limitations on patenting natural genes. However, Massachusetts courts may interpret the scope of 'biotechnological innovation' more favorably to encourage local research and development than the more rigid application seen in some federal cases.
Understanding the implications of Myriad on state patent law is critical for the Massachusetts bar exam, particularly regarding biotechnology and genetic patenting issues.